Tech Company Financing Transactions
Gensaic Funding Round
Cystic Fibrosis Foundation joined a $3.5 million venture round for Gensaic. The funding round was announced on 1/9/2023.
Transaction Overview
Company Name
Announced On
1/9/2023
Transaction Type
Venture Equity
Amount
$3,500,000
Round
Undisclosed
Investors
Cystic Fibrosis Foundation (Lead Investor)
Proceeds Purpose
Gensaic will harness its proprietary PDP platform to achieve pre-clinical milestones upon which the 2nd tranche will be transacted. Gensaic will retain all rights to the continued development of a lead program.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
700 Main St,
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Founded within MIT campus, we are a diverse team of phage and biological engineers harnessing the human phageome to develop a next-generation delivery platform for redosable genomic medicines. We believe in thinking outside of the box and are pioneering a multidisciplinary approach in developing our phage-derived particle (PDP) technology for in-vivo gene therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lavi Erisson
Chief Technical Officer
Jonathan Hsu
Browse more venture capital transactions:
Prev: 1/9/2023: Qritive venture capital transaction
Next: 1/9/2023: Spiral Therapeutics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs